Radionuclide Imaging of Cardiac Device Infection

Current Cardiovascular Imaging Reports

Volumn 10, Issue 4, 2017, Pages

  Green, Roberta ^a   Cantoni, Valeria ^a   Nappi, Carmela ^a   Gaudieri, Valeria ^a,b   Zampella, Emilia ^a   Assante, Roberta ^a   Acampa, Wanda ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

Cardiac implantable electrophysiological devices; Echocardiography; PET CT; Radionuclide imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CARDIOVASCULAR EQUIPMENT; CLINICAL DECISION MAKING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DEVICE INFECTION; HUMAN; LEUKOCYTE; LUNG PARENCHYMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROSTHETIC VALVE ENDOCARDITIS; REVIEW; RISK FACTOR; SCINTISCANNING; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 85014014889     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-017-9406-4     Document Type: Review

References (22)

1. Nof E, Epstein LM. Complications of cardiac implants: handling device infections. Eur Heart J. 2013;34(3):229–36. Review.
2. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol. 2010;33(4):414–9.
3. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med. 2011;171(20):1821–8.
4. Baman TS, Gupta SK, Valle JA, Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol. 2009;2(2):129–34.
5. •• Baddour LM, Epstein AE, Erickson CC, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in Young, Council on Cardiovascular Surgery and Anesthesia, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121(3):458–77. The American Heart Association commissioned this scientific statement to educate clinicians about CIED infections, to provide explicit recommendations for the care of patients with suspected or established CIED infections, and to define the areas of needed research. This document has addressed critical aspects of CIED infections and management strategies, and a summary of recommendations have been presented.
6. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart. 2009;95(9):715–20.
7. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116(12):1349–55.
8. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49(18):1851–9.
9. Da Costa A, Lelièvre H, Kirkorian G, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation. 1998;97(18):1791–5.
10. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect. 2002;4(4):481–9. Review.
11. • Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother. 2015;70(2):325–59. This guideline aims to improve the quality of care in patients with CIEDs, providing an educational resource for all relevant healthcare professionals, encouraging a multidisciplinary approach to CIED infection management, and promoting a standardized approach to the diagnosis, management, surveillance, and prevention of CIED infection through pragmatic evidence-rated recommendations.
12. Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol. 2012;5(2):252–7.
13. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–8.
14. Evangelista A, Flachskampf F, Lancellotti P, et al. European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. Eur J Echocardiogr. 2008;9(4):438–48.
15. Chen W, Kim J, Molchanova-Cook OP, Dilsizian V. The potential of FDG PET/CT for early diagnosis of cardiac device and prosthetic valve infection before morphologic damages ensue. Curr Cardiol Rep. 2014;16(3):459.
16. 18F-FDG-PET/CT. Eur Heart J Cardiovasc Imaging. 2015;16(5):521–30.
17. • Sarrazin JF, Philippon F, Tessier M, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol. 2012;59(18):1616–25. This study evaluated the usefulness of fluorodesoxyglucose marked by fluorine-18 (18F-FDG) positron emission tomography (PET) and computed tomography (CT) in patients with suspected cardiovascular implantable electronic device (CIED) infection. This study showed PET/CT is useful in differentiating between CIED infection and recent post-implant changes. It may guide appropriate therapy.
18. Bensimhon L, Lavergne T, Hugonnet F, et al. Whole body [(18) F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17(6):836–44.
19. Ploux S, Riviere A, Amraoui S, et al. Positron emission tomography in patients with suspected pacing system infections may play a critical role in difficult cases. Heart Rhythm. 2011;8(9):1478–81.
20. Tlili G, Amraoui S, Mesguich C, et al. High performances of (18)F-fluorodeoxyglucose PET-CT in cardiac implantable device infections: a study of 40 patients. J Nucl Cardiol. 2015;22(4):787–98.
21. Erba PA, Sollini M, Conti U, Bandera F, Tascini C, et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. JACC Cardiovasc Imaging. 2013;6(10):1075–86. Erba PA, Sollini M, Lazzeri E, Mariani G. FDG-PET in cardiac infections. Semin Nucl Med. 2013 Sep;43(5):377–95. Review
22. Rouzet F, Chequer R, Benali K, et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. J Nucl Med. 2014;55(12):1980–5.